Results 241 to 250 of about 34,732,115 (289)

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

IL-1 Receptor Antagonist Antibodies in Idiopathic Recurrent Pericarditis.

JAMA Netw Open
Wu MA, Kessel C, Fadle N, Regitz E, Fuehner S, Negro E, Berra S, Pfeifer J, Ceriani E, Thurner B, Klingel K, Caforio A, Imazio M, Brucato A, Thurner L.   +14 more
europepmc   +1 more source

Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis. [PDF]

Front Pharmacol
Wang K, Luo H, Liu L, Gao H, Song Y, Li D.   +5 more
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse. [PDF]

Leukemia
Ho TC, LaMere MW, Kawano H, Byun DK, LaMere EA, Chiu YC, Chen C, Wang LJ, Wang J, Ramdas B, Dokholyan NV, Calvi LM, Liesveld JL, Jordan CT, Singh RK, Singh RK, Kapur R, Becker MW.   +17 more
europepmc   +1 more source

Use of an IL-1 Inhibitor for Refractory Steroid-Dependent Lupus Pericarditis With Constrictive Physiology. [PDF]

JACC Case Rep
Creechan P, Lockwood M, Weber BN, Klein A, Haider SW.   +4 more
europepmc   +1 more source

Disproportionality Analysis of Adverse Events Associated with IL-1 Inhibitors in the FDA Adverse Event Reporting System (FAERS). [PDF]

Pharmaceuticals (Basel)
Lei J, Lou Z, Jiang Y, Cui Y, Li S, Hu J, Jing Y, Yang J.   +7 more
europepmc   +1 more source

Paraprotein-Negative IL-1-Mediated Inflammatory Dermatosis: An Update on Schnitzler-Like Syndrome in the Absence of a Gammopathy. [PDF]

JID Innov
Ahmad R, Dunne J, Ridge K, Fagan N, Conlon N.   +4 more
europepmc   +1 more source

Association of polycystic ovarian syndrome with inflammatory single nucleotide polymorphism for IL-1 & IL-6 genes: A case-control study. [PDF]

Indian J Med Res
Benjamin JJ, Ramaswamy P, Kuppusamy MK, Vembu R, Rajamani K, Puttaswamy N, Narayanasa MK, Mathews RR, Koshy T.   +8 more
europepmc   +1 more source

IL-1 Pathway Inhibition in Recurrent Pericarditis Management: Real-World Adoption of Corticosteroid Sparing in RESONANCE. [PDF]

JACC Adv
Cremer PC, Luis SA, Garshick MS, Raisinghani A, Weber B, Winnowski D, Clair J, Parameswaran V, Curtis A, Klein AL, Paolini JF, RESONANCE Study Group.   +11 more
europepmc   +1 more source